Factor V Leiden - Revision history

Danbot: Add Category:Labs

2026-03-22T06:44:00Z

← Revisión anterior		Revisión del 06:44 22 mar 2026
Línea 42:		Línea 42:

	[[Category:Heme/Onc]]		[[Category:Heme/Onc]]
			[[Category:Labs]]

Danbot: Expand: risk stratification, do NOT order workup acutely, standard anticoagulation

2026-03-21T01:48:00Z

Expand: risk stratification, do NOT order workup acutely, standard anticoagulation

← Revisión anterior		Revisión del 01:48 21 mar 2026
Línea 1:		Línea 1:
	==Background==		==Background==
	*~~Also known as Factor V Leiden Deficiency or FVL~~		*Most common inherited thrombophilia (3-8% of Caucasians)
	*Point mutation in FV making it resistant to cleavage by activated protein C		*Point mutation in Factor V making it resistant to cleavage by activated protein C → hypercoagulable state
	*~~Increased~~ risk of ~~thrombosis~~		*Heterozygous: 3-8× increased risk of VTE; Homozygous: 50-80× increased risk
	*Most individuals with FVL will never ~~have~~ a venous thromboembolism (VTE)		*Most individuals with FVL will never develop a [[DVT\|venous thromboembolism (VTE)]]
			*'''EM relevance:''' Presents when a provoking factor (OCP use, surgery, immobilization, pregnancy) unmasks the predisposition

	==Clinical Features==		==Clinical Features==
	*~~Family history of thrombophilia~~		*[[DVT]], [[pulmonary embolism]]
	*VTE at a young age		*VTE at young age (<50 years) without clear provoking factor
	*VTE in an atypical ~~location~~		*VTE in atypical locations (mesenteric, cerebral venous sinus)
			*Recurrent VTE
			*Family history of VTE or known thrombophilia

	==Differential Diagnosis==		==Differential Diagnosis==
Línea 14:		Línea 17:

	==Evaluation==		==Evaluation==
	~~===Workup===~~		*Activated protein C resistance assay — screening test
			*Factor V Leiden genetic testing — confirmatory
	~~===Diagnosis===~~		*'''Do NOT order thrombophilia workup in the acute ED setting''' — anticoagulation and acute illness affect results
			*Thrombophilia testing should be deferred to outpatient hematology follow-up

	==Management==		==Management==
			*'''Acute VTE:''' Standard anticoagulation per [[DVT]] or [[pulmonary embolism]] guidelines (same as non-FVL patients)
			*'''Duration of anticoagulation''' (hematology decision):
			**First provoked VTE: 3-6 months
			**Unprovoked VTE or recurrent VTE: consider indefinite anticoagulation
			*Asymptomatic FVL carriers: no prophylactic anticoagulation; counsel on risk reduction

	==Disposition==		==Disposition==
			*Per underlying VTE management
			*Ensure hematology follow-up for thrombophilia evaluation after acute treatment

	==See Also==		==See Also==
			*[[DVT]]
			*[[Pulmonary embolism]]
	~~==External Links==~~		*[[Coagulopathy (Main)]]


	==References==		==References==

Elcatracho: /* Differential Diagnosis */

2021-01-25T05:15:42Z

Differential Diagnosis

← Revisión anterior		Revisión del 05:15 25 ene 2021
Línea 11:		Línea 11:

	==Differential Diagnosis==		==Differential Diagnosis==
	*[[Disseminated Intravascular Coagulation (DIC)]]		{{Increased clotting DDX}}

	==Evaluation==		==Evaluation==

Elcatracho: /* Differential Diagnosis */

2021-01-25T05:05:24Z

Differential Diagnosis

← Revisión anterior		Revisión del 05:05 25 ene 2021
Línea 11:		Línea 11:

	==Differential Diagnosis==		==Differential Diagnosis==
			*[[Disseminated Intravascular Coagulation (DIC)]]

	==Evaluation==		==Evaluation==

Elcatracho: /* References */

2021-01-25T05:04:06Z

References

← Revisión anterior		Revisión del 05:04 25 ene 2021
Línea 33:		Línea 33:
	<references/>		<references/>

	[[Category:~~HematologyandOncology~~]]		[[Category:Heme/Onc]]

Elcatracho: /* References */

2021-01-25T05:03:24Z

References

← Revisión anterior		Revisión del 05:03 25 ene 2021
Línea 33:		Línea 33:
	<references/>		<references/>

	[[Category:~~Hematology and Oncology~~]]		[[Category:HematologyandOncology]]

Elcatracho: /* References */

2021-01-25T05:02:29Z

References

← Revisión anterior		Revisión del 05:02 25 ene 2021
Línea 33:		Línea 33:
	<references/>		<references/>

	[Category:Hematology and Oncology]		[[Category:Hematology and Oncology]]

Elcatracho: /* References */

2021-01-25T05:01:54Z

References

← Revisión anterior		Revisión del 05:01 25 ene 2021
Línea 32:		Línea 32:
	==References==		==References==
	<references/>		<references/>

			[Category:Hematology and Oncology]

Farmersj333: /* Clinical Features */

2021-01-03T20:19:57Z

Clinical Features

← Revisión anterior		Revisión del 20:19 3 ene 2021
Línea 6:		Línea 6:

	==Clinical Features==		==Clinical Features==
	*~~family~~ history of thrombophilia		*Family history of thrombophilia
	*VTE at a young age		*VTE at a young age
	*VTE in an atypical location		*VTE in an atypical location

Farmersj333: Created page with "==Background== Also known as Factor V Leiden Deficiency or FVL Point mutation in FV making it resistant to cleavage by activated protein C Increased risk of thrombosis Mos..."

2021-01-03T20:19:22Z

Created page with "==Background== *Also known as Factor V Leiden Deficiency or FVL *Point mutation in FV making it resistant to cleavage by activated protein C *Increased risk of thrombosis *Mos..."

Página nueva

==Background==
*Also known as Factor V Leiden Deficiency or FVL
*Point mutation in FV making it resistant to cleavage by activated protein C
*Increased risk of thrombosis
*Most individuals with FVL will never have a venous thromboembolism (VTE)

==Clinical Features==
*family history of thrombophilia
*VTE at a young age
*VTE in an atypical location

==Differential Diagnosis==

==Evaluation==
===Workup===

===Diagnosis===

==Management==

==Disposition==

==See Also==

==External Links==

==References==
<references/>

Factor V Leiden - Revision history

Danbot: Add Category:Labs

Danbot: Expand: risk stratification, do NOT order workup acutely, standard anticoagulation

Elcatracho: /* Differential Diagnosis */

Elcatracho: /* Differential Diagnosis */

Elcatracho: /* References */

Elcatracho: /* References */

Elcatracho: /* References */

Elcatracho: /* References */

Farmersj333: /* Clinical Features */

Farmersj333: Created page with "==Background== *Also known as Factor V Leiden Deficiency or FVL *Point mutation in FV making it resistant to cleavage by activated protein C *Increased risk of thrombosis *Mos..."

Farmersj333: Created page with "==Background== Also known as Factor V Leiden Deficiency or FVL Point mutation in FV making it resistant to cleavage by activated protein C Increased risk of thrombosis Mos..."